Clinical Trial: NRG GY020

NRG GY020

Status: Closed

A Phase III Randomized Trial of Radiation +/- Pembrolizumab (MK-3475) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer

GY020 is closed to accrual, effective August 29, 2022